Rajaraman Swaminathan - Epidemiology

Author Information

Rajaraman Swaminathan is affiliated with the Department of Epidemiology, Biostatistics and Cancer Registry at the Cancer Institute in Chennai, India. His research predominantly revolves around cancer epidemiology, with a particular focus on breast and cervical cancer. He has made significant contributions to understanding cancer trends in India and developing diagnostic and prognostic tools for various types of cancer.

Research Contributions

Rajaraman Swaminathan has authored numerous impactful papers in the field of cancer epidemiology. His research spans diverse topics, such as the identification and validation of plasma biomarkers for breast cancer diagnosis in South Asian women, the real-world outcomes of patients with locally advanced breast cancer, and trends in breast and cervical cancer under the National Cancer Registry Programme in India. He has also contributed to the development of pediatric cancer prognosticator guidelines and investigated the expression of cancer stem cell markers in ovarian tumors. Additionally, his work includes evaluating cytogenetic abnormalities in acute lymphoblastic leukemia and analyzing cancer survival in transitional countries, with a focus on Asia.

Aliases

R Swaminathan, R. Swaminathan, Rajaraman Swaminathan

Publication and Citation Metrics

Metric	Value
Citation Count	6053
h-index	32
Paper Count	91

Publications:

Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women

DOI: 10.1038/s41598-021-04176-w

Year: 2022

Locally Advanced Breast Cancer (LABC): Real-World Outcome of Patients From Cancer Institute, Chennai

DOI: 10.1200/GO.21.00001

Year: 2021

Trends in breast and cervical cancer in India under National Cancer Registry Programme: An Age-Period-Cohort analysis.

DOI: 10.1016/j.canep.2021.101982

Year: 2021

Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines.

DOI: 10.1016/s1470-2045(20)30320-x

Year: 2020

Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours.

DOI: 10.3233/cbm-201463

Year: 2020

Relevance of tumor node metastasis staging in salivary gland tumors – a retrospective analysis from a tertiary cancer center

DOI: 10.4103/oji.oji_34_19

Year: 2020

Evaluation of Cytogenetic Abnormalities in Patients with Acute Lymphoblastic Leukemia

DOI: 10.1007/s12288-019-01123-8

Year: 2019

Cancer survival in countries in transition, with a focus on selected Asian countries

DOI:

Year: 2019

Essential TNM: a registry tool to reduce gaps in cancer staging information.

DOI: 10.1016/S1470-2045(18)30897-0

Year: 2019

The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990–2016

DOI: 10.1016/S1470-2045(18)30447-9

Year: 2018

What Are Third Party Service Providers?

What Are Examples of Secondary Prevention?

What are Coverage Gaps?

What is the Impact of Cultural Competency in Healthcare?

What Are the Challenges in Managing Agricultural Waste?

What are Some Challenges in Implementing Effective Treatments?

Why is Understanding Epidemic Trends Important?

Why Focus on a Limited Spectrum?

Why are Drug Interactions Important in Epidemiology?

What is Environmental Control?

Partnered Content Networks

Relevant Topics